UCB Takes Over Candid, Odyssey’s IPO & Makary’s Rough Week

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.